<DOC>
	<DOCNO>NCT01686217</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics ( PK ) profile three different strength ASP015K extend release formulation immediate release formulation evaluate food effect extend release strength healthy volunteer .</brief_summary>
	<brief_title>A Phase I Study Compare 3 Different Strengths Extended Release Formulation ASP015K Immediate Release Formulation ASP015K</brief_title>
	<detailed_description>Study involve 3 parallel group . Subjects group receive 3 single-dose treatment washout period least 7 day separate dose two consecutive treatment . Dosing condition include feed fasted condition .</detailed_description>
	<criteria>The subject must weigh least 45 kg body mass index ( BMI ) 1832 kg/m2 , inclusive Screening If female , subject surgically sterile ( documentation provide healthcare professional ) , postmenopausal ( define least 2 year since last regular menstrual cycle confirmatory follicle stimulate hormone ( FSH ) level ≥ 30 U/L screen ) subject pregnant document negative serum pregnancy test Screening Day 1 lactate If male , subject agree sexual abstinence , surgically sterile ( documentation provide healthcare professional ) use medically acceptable method prevent pregnancy agree continue use method study 90 day last dose study drug administration Male subject must agree donate sperm study 90 day last dose study drug administration The subject 's 12lead electrocardiogram ( ECG ) normal Screening Day 1 initial treatment period , abnormal , abnormality clinically significant determine Investigator The subject 's clinical laboratory test result Screening Day 1 within normal limit unless Investigator consider abnormality `` clinically significant '' The subject medically healthy , clinically significant medical history abnormality observe upon physical examination determine Investigator The subject willing able comply study requirement The subject must capable swallow multiple tablet The subject able consume FDA high fat breakfast within 30 minute The subject previous history clinically significant gastrointestinal , neurological , renal , hepatic , pulmonary , metabolic , cardiovascular , psychiatric , endocrine , hematological disorder disease , malignancy exclude nonmelanoma skin cancer medical condition , Investigator 's opinion , would preclude participation study The subject major GI surgery ( colectomy , cholecystectomy , etc ) may inhibit absorption and/or metabolism study drug The subject history consume 14 unit alcoholic beverage per week history alcoholism drug/chemical/ substance abuse within past 2 year prior Screening ( Note : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) The subject positive test alcohol drug abuse Screening Day 1 The subject positive cotinine test Screening Day 1 The subject treatment prescription , nonprescription complementary alternative medicine ( CAM ) within 14 day prior Day 1 ( initial treatment period ) exception stable hormone replacement therapy ( HRT ) and/or occasional use acetaminophen ( maximum 2 g/day ) The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior Day 1 The subject positive test hepatitis C antibody , positive test hepatitis B surface antigen ( HBsAg ) , positive hepatitis B core antibody Screening The subject history human immunodeficiency virus ( HIV ) antibody The subject positive tuberculosis ( TB ) skin test , Quantiferon Gold test TSPOT® test Screening The subject receive vaccine within 60 day prior study drug administration The subject receive experimental agent within 30 day five halflives , whichever longer , prior study drug administration The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 1 The subject absolute neutrophil count ( ANC ) &lt; 2500 cells/mm3 CPK &gt; 1.5x upper limit normal Screening Day 1 initial treatment period The subject smoke use tobaccocontaining product nicotine nicotinecontaining product past six month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ASP015K Extended Release</keyword>
	<keyword>ASP015K Immediate Release</keyword>
	<keyword>Food Effect</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>